The evaluation of the results in the use of cannabidiol in a child with epileptic seizures
DOI:
https://doi.org/10.33448/rsd-v12i3.40524Keywords:
Cannabidiol; Epilepsy; Cerebral palsy.Abstract
Objective: To investigate whether the use of Cannabidiol in children diagnosed with Cerebral Palsy improves motor function and reduces epileptic seizures associated with this pathology. Methodology: This integrative literature review was carried out by collecting data through searches of studies in the databases: National Library of Medicine National Institutes of Health (PubMed) and Virtual Health Library (BVS). Inclusion criteria will consider original articles, published in online databases in the period between 2017 and 2022, in Portuguese, English and Spanish. The descriptors that were used in this study were “Cerebral Palsy” AND “Cannabidiol”, “Cerebral Palsy” AND “Cannabidiol”, “Cannabidiol” AND “Epilepsy” and “Cannabidiol” AND “Epilepsia”. Results: 13 articles were selected, in which it is possible to show that the use of cannabidiol for the treatment of seizures and motor symptoms in children brings benefits such as the reduction in the frequency of seizures. The results of scientific studies obtained so far on the use of CBD in clinical applications may represent hope for patients who are resistant to all conventional antiepileptic drugs. Conclusion: There is still a scarcity of published data, thus preventing the full recommendation of its use for medicinal purposes in pediatrics in cases of epilepsy.
References
Caraballo, R., Demirdjian, G., Reyes, G., Huaman, M., & Gutierrez, R. (2020). Effectiveness of cannabidiol in a prospective cohort of children with drug-resistant epileptic encephalopathy in Argentina. Seizure: The Journal of the British Epilepsy Association, 80, 75–80. https://doi.org/10.1016/j.seizure.2020.06.005
De Carvalho, C. R., Franco, P. L. C., Eidt, I., Hoeller, A. A., & Walz, R. (2017). Canabinoides E Epilepsia: Potencial Terapêutico Do Canabidiol. Vittalle - Revista de Ciências da Saúde, 29(1), 54–63. https://doi.org/10.14295/vittalle.v29i1.6292
Diretrizes de atenção à pessoa com paralisia cerebral / Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Ações Programáticas Estratégicas. (2014).
Elliott, J., DeJean, D., Clifford, T., Coyle, D., Potter, B. K., Skidmore, B., Alexander, C., Repetski, A. E., Shukla, V., McCoy, B., & Wells, G. A. (2020). Cannabis-based products for pediatric epilepsy: An updated systematic review. Seizure: The Journal of the British Epilepsy Association, 75, 18–22. https://doi.org/10.1016/j.seizure.2019.12.006
Espinosa-Jovel, C. (2020). Cannabinoides en epilepsia: eficacia clínica y aspectos farmacológicos. Neurología (English Edition), 38(1), 49–55. https://doi.org/10.1016/j.nrl.2020.02.005
Fairhurst, C., Kumar, R., Checketts, D., Tayo, B., & Turner, S. (2020). Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Developmental Medicine and Child Neurology, 62(9), 1031–1039. https://doi.org/10.1111/dmcn.14548
Huntsman, R. J., Tang-Wai, R., Alcorn, J., Vuong, S., Acton, B., Corley, S., Laprairie, R., Lyon, A. W., Meier, S., Mousseau, D. D., Newmeyer, D., Prosser-Loose, E., Seifert, B., Tellez-Zenteno, J., Huh, L., Leung, E., & Major, P. (2019). Dosage related efficacy and tolerability of Cannabidiol in Children with treatment-resistant epileptic encephalopathy: Preliminary results of the CARE-E study. Frontiers in Neurology, 10, 716. https://doi.org/10.3389/fneur.2019.00716
Klotz, K. A., Grob, D., Schönberger, J., Nakamura, L., Metternich, B., Schulze-Bonhage, A., & Jacobs, J. (2021). Effect of cannabidiol on interictal epileptiform activity and sleep architecture in children with intractable epilepsy: A prospective open-label study. CNS Drugs, 35(11), 1207–1215. https://doi.org/10.1007/s40263-021-00867-0
Libzon, S., Schleider, L. B.-L., Saban, N., Levit, L., Tamari, Y., Linder, I., Lerman-Sagie, T., & Blumkin, L. (2018). Medical cannabis for pediatric moderate to severe complex motor disorders. Journal of Child Neurology, 33(9), 565–571. https://doi.org/10.1177/0883073818773028
Matos, R. L., Spinola, L. A., Barboza, L. L., Garcia, D. R., França, T. C., & Affonso, R. S. (2017). O uso do canabidiol no tratamento da epilepsia. Revista Virtual de Química, 9(2), 786–814.
Michael-Asalu, A., Taylor, G., Campbell, H., Lelea, L.-L., & Kirby, R. S. (2019). Cerebral palsy: Diagnosis, epidemiology, genetics, and clinical update. Advances in Pediatrics, 66, 189–208. https://doi.org/10.1016/j.yapd.2019.04.002
Mitelpunkt, A., Kramer, U., Hausman Kedem, M., Zilbershot Fink, E., Orbach, R., Chernuha, V., Fattal-Valevski, A., Deutsch, L., Heffetz, D., & Sacks, H. (2019). The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Epilepsy & Behavior: E&B, 98(Pt A), 233–237. https://doi.org/10.1016/j.yebeh.2019.07.007
Oshiro, C. A., & Castro, L. H. M. (2022). Cannabidiol and epilepsy in Brazil: a current review. Arquivos de Neuro-Psiquiatria, 80(5 Suppl 1), 182–192. https://doi.org/10.1590/0004-282X-ANP-2022-S137
Patel, D. R., Neelakantan, M., Pandher, K., & Merrick, J. (2020). Cerebral palsy in children: a clinical overview. Translational Pediatrics, 9(Suppl 1), S125–S135. https://doi.org/10.21037/tp.2020.01.01
Pernoncini, K. V., & Oliveira, R. M. M. (2014). Usos Terapêuticos Potenciais Do Canabidiol Obtido Da Cannabis sativa. Uningá Review, 20(3). https://revista.uninga.br/uningareviews/article/view/1609
Pesantez-Rios, G., Armijos-Acurio, L., Jimbo-Sotomayor, R., Pascual-Pascual, S. I., & Pesantez-Cuesta, G. (2017). Cannabidiol: its use in refractory epilepsies. Revista de neurologia, 65(4), 157–160.
Scheffer, I. E., Hulihan, J., Messenheimer, J., Ali, S., Keenan, N., Griesser, J., Gutterman, D. L., Sebree, T., & Sadleir, L. G. (2021). Safety and tolerability of transdermal cannabidiol gel in children with developmental and epileptic encephalopathies: A nonrandomized controlled trial: A nonrandomized controlled trial. JAMA Network Open, 4(9), e2123930. https://doi.org/10.1001/jamanetworkopen.2021.23930
Schier, A. R. de M., Ribeiro, N. P. de O., Silva, A. C. de O. e., Hallak, J. E. C., Crippa, J. A. S., Nardi, A. E., & Zuardi, A. W. (2012). Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Revista Brasileira de Psiquiatria (Sao Paulo, Brazil: 1999), 34 Suppl 1, S104-10. https://doi.org/10.1590/s1516-44462012000500008
Sheffali. (2018). Cerebral palsy: an overview. The Indian Journal of Pediatrics, 11, 1006–1016.
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials. Molecules (Basel, Switzerland), 24(8), 1459. https://doi.org/10.3390/molecules24081459
Szaflarski, J. P., Bebin, E. M., Cutter, G., DeWolfe, J., Dure, L. S., Gaston, T. E., Kankirawatana, P., Liu, Y., Singh, R., Standaert, D. G., Thomas, A. E., Ver Hoef, L. W., & UAB CBD Program. (2018). Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy & Behavior: E&B, 87, 131–136. https://doi.org/10.1016/j.yebeh.2018.07.020
Williams, C. M., & Stephens, G. J. (2020). Development of cannabidiol as a treatment for severe childhood epilepsies. British Journal of Pharmacology, 177(24), 5509–5517. https://doi.org/10.1111/bph.15274
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Lozany Vieira de Jesus; Maiara Mendes Costa; Marcos Henrique Gonzales; Oswaldo José Marcelino Neto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
